双成药业(002693) - 2025 Q2 - 季度业绩预告

Performance Forecast and Financial Indicators The company anticipates continued losses in the first half of 2025, with net profit attributable to shareholders projected to be a loss of 13 million to 19 million yuan, while operating revenue is expected to decline year-over-year to a range of 75 million to 95 million yuan Performance Forecast Summary | Item | Current Period (2025 H1 Forecast) | Prior Period (2024 H1) | | :--- | :--- | :--- | | Net Profit Attributable to Shareholders of Listed Company (Million Yuan) | Loss: 13 – 19 | Loss: 16.9462 | | Year-over-Year Change | Profit Decrease 12.12% to Profit Increase 23.29% | - | | Net Profit After Deducting Non-recurring Gains and Losses (Million Yuan) | Loss: 15.55 – 21.55 | Loss: 17.7595 | | Basic Earnings Per Share (Yuan/Share) | Loss: 0.0313 – 0.0458 | Loss: 0.0409 | | Operating Revenue (Million Yuan) | 75 – 95 | 94.8926 | | Operating Revenue After Deduction (Million Yuan) | 72 – 92 | 92.5754 | Operating Performance and Attribution The company's overall performance remained relatively stable due to mixed results from domestic and international operations, with domestic profit decline offset by international sales growth and a positive impact from non-recurring gains - Domestic business profit declined due to the centralized drug procurement policy, leading to decreased sales of non-winning bids and significant price reductions for winning bids like Thymosin Alpha 1 for Injection, reducing domestic sales profit[4] - Export business profit increased as Paclitaxel (Albumin-bound) for Injection received US FDA approval in May 2025 and began export sales, alongside growth in Bivalirudin for Injection export revenue[4][5] - Non-recurring gains and losses contributed approximately 2.55 million yuan, primarily from government subsidies and investment income[5] Important Notes and Risk Factors The company faces severe delisting risks due to its 2024 financial performance, with its stock already under *ST warning, and potential termination of listing if 2025 performance fails to meet standards, noting that this preliminary forecast is unaudited - The company's stock faces delisting risk as it was placed under a delisting risk warning (*ST) from April 30, 2025, due to negative audited net profit and operating revenue after deduction below 300 million yuan in 2024[6] - Failure to meet performance standards in 2025 could trigger Article 9.3.12 of the Shenzhen Stock Exchange Listing Rules, leading to the termination of the company's stock listing[6] - This performance forecast is a preliminary estimation by the company's finance department and has not been audited by an accounting firm, thus subject to uncertainty[3][6]